CHADS2 Score

The CHADS2 Score is a foundational clinical prediction tool for estimating stroke risk in patients with non-valvular atrial fibrillation. Developed by Gage and colleagues in 2001, this scoring system became the first widely adopted, validated tool for guiding anticoagulation decisions in AF and fundamentally changed the approach to stroke prevention in this patient population. While largely superseded by the more refined CHA2DS2-VASc score in current guidelines, the CHADS2 score remains an important reference point in cardiovascular medicine.

The acronym CHADS2 represents five risk factors: Congestive heart failure (1 point), Hypertension (1 point), Age 75 years or older (1 point), Diabetes mellitus (1 point), and prior Stroke or transient ischemic attack (2 points, hence the subscript 2). The maximum score is 6. The score was derived by combining elements from two earlier prediction schemes, the Atrial Fibrillation Investigators (AFI) scheme and the Stroke Prevention in Atrial Fibrillation (SPAF) investigators criteria, and validated in the National Registry of Atrial Fibrillation (NRAF) cohort of 1,733 Medicare beneficiaries.

The original validation study demonstrated a clear stepwise increase in stroke rate with increasing CHADS2 score, from 1.9% per year at a score of 0 to 18.2% per year at a score of 6. For each 1-point increase in score, the stroke rate increased by approximately 1.5-fold. The C-statistic for the CHADS2 score in the derivation cohort was 0.82, indicating good discriminative ability for identifying patients at higher stroke risk.

Treatment recommendations based on the CHADS2 score were stratified into three tiers in the original framework: a score of 0 suggested low risk suitable for aspirin therapy or no antithrombotic therapy, a score of 1 indicated moderate risk where either aspirin or oral anticoagulation was reasonable, and a score of 2 or higher indicated high risk warranting oral anticoagulation with warfarin (with DOACs now available as alternatives). This framework provided a clear, simple decision tool for clinicians managing the large and growing population of AF patients.

The primary limitation of the CHADS2 score that led to development of the CHA2DS2-VASc score was its classification of a large proportion of patients as moderate risk (score 1), where the treatment recommendation was ambiguous. The CHA2DS2-VASc score addressed this by adding three additional risk factors (vascular disease, age 65-74, and female sex) and weighting age 75 and prior stroke at 2 points. This refinement improved identification of truly low-risk patients who could safely forgo anticoagulation and reduced the size of the intermediate-risk group.

Despite being largely replaced in guideline recommendations, the CHADS2 score contributed immensely to cardiovascular medicine by establishing the principle of risk-stratified anticoagulation in atrial fibrillation. It demonstrated that a simple, easily calculated scoring system could effectively guide treatment decisions, improving outcomes by ensuring high-risk patients received appropriate anticoagulation while avoiding unnecessary treatment in low-risk patients. The CHADS2 score remains in use in some clinical settings and is still referenced in many treatment algorithms and clinical decision support tools worldwide.